...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
【24h】

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

机译：阻止GD2的有针对性的免疫治疗和潜在的价值循环microrna在神经母细胞瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy. Despite significant progress in treatment of NB afflicted patients, high risk disease is usually associated with poor outcome, resulting in long‐term survival of less that 50%. Known as a disease most commonly originated form the nerve roots, the variants involved in NB imitation and progression remain to be elucidated. The outcome of low to intermediate risk disease is favorable whereas the high risk NB disease with dismal prognosis, positing the necessity of novel approaches for early detection and prognostication of advanced disease. Tailored immunotherapy approaches have shown significant improvement in high‐risk NB patients. It has found a link between Gangliosides and progression of NB. The vast majority of neuroblastoma tumors express elevated levels of GD2, opening new insight into using anti‐GD2 drugs as potential treatments for NBs. Implication of anti‐GD2 monoclonal antibodies for treatment of high risk NBs triggers further investigation to unearth novel biomarkers as prognostic and response biomarker to guide additional multimodal tailored treatment approaches. A growing body of evidence supports the usefulness of miRNAs to evaluate high risk NBs response to anti‐GD2 drugs and further prevent drug‐related toxicities in refractory or recurrent NBs. miRNAs and circulating proteins in body fluids (plasma and serum) present as potential biomarkers in early detection of NBs. Here, we summarize various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB. We further attempted to overview prognostic biomarkers in response to treatment with anti‐GD2 drugs.
机译：与不同的临床神经母细胞瘤(NB)演讲是一种已知的儿童恶性肿瘤。尽管治疗NB的重大进展折磨的病人,通常是高危疾病预后不良,导致长期生存的少50%。神经疾病最常见的是形式根,NB模仿和所涉及的变体发展仍有待阐明。中间风险低的疾病是有利的而高风险NB疾病与沮丧预后,假定小说的必要性早期发现和方法先进的疾病的预测。免疫治疗方法显示显著改善高危险NB的病人。找到了一个神经节甘脂和发展之间的联系NB。表达水平升高阻止GD2,打开新的了解使用反事故阻止GD2作为潜在的药物国家统计局的治疗方法。单克隆抗体治疗的风险很高国家统计局触发进一步的调查发掘新型生物标志物作为预后和响应生物标志物指导额外的多通道量身定做治疗方法。支持microrna评估的有效性高风险国家统计局回应反阻止GD2药物和进一步防止药物相关毒性难治性或复发性国家统计局。循环在体液(等离子体和蛋白质血清)早期的潜在生物标志物国家统计局的检测。生物标志物参与诊断、预后和患者对治疗的反应NB。进一步试图概述预后生物标志物与反阻止GD2应承担对治疗的反应药物。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号